MERS-related coronavirus

Virus that causes Middle East respiratory syndrome (MERS)

MERS-related coronavirus (MERS-CoV) is a virus belonging to the genus Betacoronavirus, which is part of the family Coronaviridae. It is the causative agent of Middle East respiratory syndrome (MERS), a viral respiratory illness first reported in Saudi Arabia in 2012. MERS-CoV is a zoonotic virus, meaning it is transmitted between animals and humans.

Virology

MERS-CoV is an enveloped virus with a positive-sense single-stranded RNA genome. It is classified within the Betacoronavirus genus, which also includes the SARS-related coronavirus and the SARS-CoV-2 virus responsible for the COVID-19 pandemic. The virus is characterized by its spike protein, which facilitates entry into host cells by binding to the DPP4 receptor.

MERS-CoV electron micrograph

Genome

The genome of MERS-CoV is approximately 30 kilobases in length, encoding several structural and non-structural proteins. The major structural proteins include the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The spike protein is particularly important for the virus's ability to infect host cells and is a target for vaccine development.

Transmission

MERS-CoV is primarily transmitted from animals to humans, with dromedary camels identified as a major reservoir host. Human-to-human transmission can occur, particularly in healthcare settings, but is less common. The virus spreads through respiratory droplets, and close contact with infected individuals increases the risk of transmission.

Clinical Features

MERS-CoV infection can range from asymptomatic or mild respiratory symptoms to severe acute respiratory disease and death. Common symptoms include fever, cough, and shortness of breath. Severe cases can lead to pneumonia and kidney failure. The case fatality rate is estimated to be around 35%.

MERS-CoV in a laboratory setting

Diagnosis

Diagnosis of MERS-CoV infection is typically confirmed through reverse transcription polymerase chain reaction (RT-PCR) testing of respiratory samples. Serological tests can also be used to detect antibodies against the virus, indicating past infection.

Prevention and Treatment

Currently, there is no specific antiviral treatment or vaccine for MERS-CoV. Management of the disease is primarily supportive, focusing on relieving symptoms and providing respiratory support when necessary. Preventive measures include infection control practices in healthcare settings and minimizing contact with camels in affected regions.

Epidemiology

Since its emergence in 2012, MERS-CoV has been reported in 27 countries, with the majority of cases occurring in the Middle East. Outbreaks have been associated with healthcare settings, and the virus has a high potential for nosocomial transmission.

3D print of MERS-CoV spike protein

Research

Ongoing research efforts are focused on understanding the virus's transmission dynamics, developing effective vaccines, and identifying potential therapeutic agents. Studies on the virus's structure and function are crucial for the development of targeted interventions.

Related pages

• Middle East respiratory syndrome
• Coronavirus
• Zoonosis
• SARS-related coronavirus
• SARS-CoV-2